Terani Robertson
Family · Russell Springs, KYNPI 1922315266
Payments from drug & device makers
Across 220 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$695
- AbbVie$432
- Novo Nordisk$427
- Lilly USA, LLC$281
- Novartis$275
- Bayer$241
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,738100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $695 |
| AbbVie | 30 | $432 |
| Novo Nordisk | 27 | $427 |
| Lilly USA, LLC | 20 | $281 |
| Novartis | 18 | $275 |
| Bayer | 15 | $241 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $223 |
| Boehringer Ingelheim | 13 | $202 |
| Pfizer | 9 | $152 |
| GSK | 7 | $132 |
| Amgen(2 entities) | 8 | $131 |
| Shield Therapeutics Inc | 1 | $79 |
| Abbott | 5 | $74 |
| Vanda Pharmaceuticals Inc. | 3 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 2 | $44 |
| Exact Sciences | 3 | $44 |
| Astellas Pharma US Inc | 3 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $32 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Merck | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,747 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $228,871 |
| EliquisApixaban | 115 | $85,928 |
| FarxigaDapagliflozin Propanediol | 120 | $84,688 |
| JardianceEmpagliflozin | 74 | $61,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $39,791 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $38,283 |
| JanuviaSitagliptin Phosphate | 37 | $36,193 |
| MounjaroTirzepatide | 33 | $33,310 |
| LinzessLinaclotide | 48 | $31,460 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $29,297 |
| XareltoRivaroxaban | 27 | $28,538 |
| TrulicityDulaglutide | 17 | $25,311 |
| RybelsusSemaglutide | 19 | $22,165 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $22,032 |
| Repatha SyringeEvolocumab | 25 | $16,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $427 | $251,036248 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $695 | $119,681171 claims |
| PfizerEliquis | $152 | $85,928115 claims |
| Boehringer IngelheimJardiance, Tradjenta | $202 | $71,98696 claims |
| Lilly USA, LLCMounjaro, Trulicity | $281 | $58,62150 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $132 | $48,32150 claims |
| MerckJanuvia, Dulera | $17 | $43,54250 claims |
| AbbVieLinzess, Synthroid | $432 | $35,700130 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $11,12117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Russell Springs
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.